We want to share a quick update and applaud one of our 50-State Network advocates Danielle Yevsa who spoke up about Fail First/ Step Therapy practices in the New York Daily News.

Salem resident Joni Johnston testified to the Missouri General Assembly’s House Emerging Issues Committee Jan. 20.

When Lauren Marchi entered college as a freshman at American University in Washington, DC, she was a classically trained pianist and ballerina. She had aspirations of pursuing degrees in piano performance and marketing while dancing on the side, but early in her senior year she was forced to question her well-laid plans.

Katherine “Kat” Macfarlane, JD, who has rheumatoid arthritis and inflammatory eye disease, spoke at a briefing held at the House of Representatives on Monday about regulation of biosimilars.

Rheumatoid arthritis patient advocates for continued access to medication in North Dakota

The U.S. Food and Drug Administration is months away from approving the first biosimilar drugs, but a bill advanced by a legislative committee Monday would help Utah prepare for that day.

For patients who are uninsured or underinsured, new treatments on the cutting edge of medicine called biosimilars have the potential to expand access and save lives.

On June 8, the state Senate debated House No. 2477/Senate No. 1705, which provides a pathway in New Jersey for access to lower-cost mimic therapies of expensive biologic drugs.

The U.S. Food & Drug Administration approved the first generic version of a biotech drug for domestic sale Friday, hours after Colorado state legislators wrestled with how to let pharmacists handle cheaper biotech drug knockoffs.

Louisiana advocate Kat MacFarlane speak about the importance of physician/patient relationships, the promise of biosimilars when made available transparently, and why she is testifying about biosimilar substitution in the legislature.